![cover image](https://wikiwandv2-19431.kxcdn.com/_next/image?url=https://upload.wikimedia.org/wikipedia/commons/thumb/f/f2/Laninamivir.svg/640px-Laninamivir.svg.png&w=640&q=50)
Laninamivir
Chemical compound / From Wikipedia, the free encyclopedia
Laninamivir (CS-8958) is a neuraminidase inhibitor that is a drug used for the treatment and prophylaxis of Influenzavirus A and Influenzavirus B.[1] It is currently in Phase III clinical trials.[2] It is a long-acting neuraminidase inhibitor administered by nasal inhalation.[3]
![]() | |
Clinical data | |
---|---|
Routes of administration | Inhalation |
ATC code | |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider |
|
UNII | |
ChEMBL | |
CompTox Dashboard (EPA) | |
Chemical and physical data | |
Formula | C13H22N4O7 |
Molar mass | 346.340 g·mol−1 |
3D model (JSmol) | |
| |
| |
![]() ![]() |
![Thumb image](http://upload.wikimedia.org/wikipedia/commons/thumb/a/ae/Inavir.jpg/640px-Inavir.jpg)
Laninamivir was approved for influenza treatment in Japan in 2010 and for prophylaxis in 2013. It is currently marketed under the name Inavir by Daiichi Sankyo. Biota Pharmaceuticals [4] and Daiichi Sankyo co-own Laninamivir. On 1 April 2011, BARDA awarded up to an estimated U$231m to Biota Pharmaceuticals (Formerly Biota Holdings Ltd) wholly owned subsidiary, Biota Scientific Management Pty Ltd, for the advanced development of Laninamivir in the US.[5] It is under clinical evaluations in other countries.[3][6]